|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The mechanisms of opioid tolerance and hyperalgesia are complex, involving μ opioid receptor signalling pathways that offer opportunities for novel analgesic alternatives.
|
30983591 |
2019 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Additionally, chronic morphine treatment-induced hyperalgesia was absent in Oprm1-cKO mice.
|
30578671 |
2019 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
At lower doses (0.003-0.03 mg/kg, s.c.) morphine induced mechanical hyperalgesia, while higher doses (1-10 mg/kg, s.c.) induced analgesia.Intrathecal (i.t.) oligodeoxynucleotide (ODN) antisense to mu-opioid receptor (MOR) mRNA, attenuated both hyperalgesia and analgesia.
|
30529265 |
2019 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Mu-opioid receptor (MOR) antisense prevented fentanyl hyperalgesia and priming.
|
29431655 |
2018 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Mu-opioid Receptor (MOR) Biased Agonists Induce Biphasic Dose-dependent Hyperalgesia and Analgesia, and Hyperalgesic Priming in the Rat.
|
30342200 |
2018 |
|
Hyperalgesia
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
We determined the serum level of melatonin and expression of μ-opioid receptor (MOR), melatonin receptor (MT1, MT2) and protein kinase C γ(PKCγ) in the spinal dorsal horn of the rats with morphine-induced hyperalgesia and tolerance.
|
28988976 |
2017 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, we theorized that MMG22 should reduce hyperalgesia in nerve-injured mice in a manner consistent with a synergistic interaction between MOR and mGluR5.
|
28891868 |
2017 |
|
Hyperalgesia
|
0.400 |
PosttranslationalModification
|
phenotype |
BEFREE |
The results support the hypothesis that locally produced estrogens in the RVM may be involved in the maintenance of chronic visceral hyperalgesia and the downstream signaling may involve phosphorylation of MOR.
|
29047208 |
2017 |
|
Hyperalgesia
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Repeated administration of mu-opioid receptor (MOR) agonists, such as DAMGO, at the peripheral terminal of the nociceptor, induces long-lasting plasticity expressed, prototypically as opioid-induced hyperalgesia and prolongation of prostaglandin E2-induced hyperalgesia.
|
28306605 |
2017 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Collectively our results show that MOR is involved in hyperalgesia induced by chronic morphine and its metabolite M3G.
|
28871199 |
2017 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, knockdown of MOR-1K in CXB7/ByJ mice via chronic intrathecal siRNA administration not only prevented the development of opioid-induced hyperalgesia, but also unmasked morphine analgesia.
|
26270813 |
2015 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In the present study, we found that three hourly injections of DAMGO (a μ-opioid receptor agonist) followed by naloxone administration at the fourth hour significantly decreased rat paw nociceptive threshold, indicating the induction of withdrawal hyperalgesia.
|
24824948 |
2014 |
|
Hyperalgesia
|
0.400 |
Biomarker
|
phenotype |
CTD_human |
Molecular interaction in the mouse PAG between NMDA and opioid receptors in morphine-induced acute thermal nociception.
|
17996026 |
2008 |